Industry Urges Korean Govt To Provide More Support To CROs
This article was originally published in PharmAsia News
Although South Korea's contract research organization (CRO) sector has grown and developed on the back of more robust R&D investments by the pharma industry, a recent report has suggested that the government should provide more systematic support to foster domestic CROs, which still lack global competitiveness due to a lack of experience.
You may also be interested in...
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
SK Biopharmaceuticals is pushing ahead with a planned sizable IPO in South Korea in June as it focuses on successfully commercializing novel anti-epileptic drug Xcopri in the US.
South Korea authorities talk to foreign media about the country's experience and successes in dealing with the COVID-19 situation, lessons learned, preparations being made to return to everyday life and R&D activity.